- Home
- EWCZ vs CRBP Comparison
EWCZ vs CRBP Comparison
Compare EWCZ & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWCZ | CRBP |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.2M | 134.8M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EWCZ | CRBP |
|---|---|---|
| Price | $5.76 | $9.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.32 | ★ $45.60 |
| AVG Volume (30 Days) | ★ 855.5K | 182.7K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $4.31 | N/A |
| Revenue Next Year | $2.09 | $99.00 |
| P/E Ratio | $21.96 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $2.95 | $4.64 |
| 52 Week High | $6.52 | $20.56 |
Technical Indicators
Market Signals| Indicator | EWCZ | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 75.00 | 57.91 |
| Support Level | $5.03 | $8.80 |
| Resistance Level | $5.84 | $9.69 |
| Average True Range (ATR) | 0.03 | 0.62 |
| MACD | -0.06 | 0.21 |
| Stochastic Oscillator | 55.00 | 62.75 |
Price Performance
Historical ComparisonAbout EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.